Eligibility of real-world patients with metastatic breast
cancer for clinical trials
by Atul Batra, Shiying Kong, Winson Y. Cheung
The Breast: Open
Access: Published: October 17, 2020
The results of clinical trials in metastatic breast cancer
(MBC) are generalized to real-world patients. This study determines the
proportion of real-world patients who would be eligible for clinical trials and
compares outcomes in eligible versus ineligible patients.
Highlights
•One third of patients with metastatic breast cancer are
clinical trial ineligible.
•Renal dysfunction and prior immunosuppression are common
reasons.
•Ineligible patients are less likely to receive
chemotherapy, but not hormonal therapy.
•Systemic treatment, but not eligibility, is associated with
overall survival.
•Eligibility criteria should be broadened to represent more
real-world patients.
